Number of patients with a significant increase or significant decrease between the baseline measurement (SCr-BL) and the creatinine measurement at emergency department presentation... by M. S. A. Niemantsverdriet (11886431)

Post-hoc analysis for visit-wise differences in dual-task learning. Significant differences between visits are indicated with an asterisk (*). by Swati M. Surkar (8399427)

Number and percentage of AE patients with detectable Em2+ antibodies at different visits and significance level in binominal test. by Beate Grüner (301524)

Time table of follow-up visits of AE patients. by Beate Grüner (301524)

Outline of study visits. by Jordan K. Abbott (8934239)

Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

Subjects:

All-variable XGBoost model on the ‘significant illness’ binary using the primary decision-maker dataset. by Richard Barrett-Jolley (739341)

Patient visit inclusion and exclusion criteria. by Brian Rice (4393609)

Subjects:

All-variable XGBoost model on the <i>significant illness</i> binary using the all-owner dataset. by Richard Barrett-Jolley (739341)

“…This shows the increasing true positive and false positive rates, with decrease of the threshold probability for prediction of <i>significant illness</i>. …”

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Proteins from volcano plot which had notable increases or decreases listed in order of greatest to least significance (adjusted p-values). by Eiman Y. Ibrahim (10731078)

Distribution of quality of life and respiratory variables scores of all 3 visits (visit = day 0, visit 2 = day 35, and visit 3 = day 70) of the PCSO-524 group and the placebo group... by Nattapon Riengvirodkij (11268720)

A flow diagram outlining the number of dogs in each group during the study (visit 1 = day 0, visit 2 = day 35, and visit 3 = day 70). by Nattapon Riengvirodkij (11268720)

Visits to the four types of alcohol outlets in each of the 16 states. by Yingjie Hu (1579000)

Subjects:

Characteristics of the ED visits. by F. Marlijn Booij-Tromp (18592092)

Subjects:

Visits and assessments, randomized period. by Natalia Teleshova (553333)

Increasing TPP side chain length decreases melanoma cell viability and clonogenic survival. by Kyle C. Kloepping (9928265)

“…Results demonstrate that TPP derivatives decrease melanoma cell viability and clonogenic survival; and there is a structure-activity relationship between TPP side chain length and decreased viability and clonogenic survival.…”

Reduced (owner-animal metadata) XGBoost model on the <i>significant illness</i> binary using the all-owner dataset. by Richard Barrett-Jolley (739341)

“…This shows the increasing true positive and false positive rates, with decrease of the threshold probability for prediction of <i>significant illness</i>. …”

The carotid canal area is larger on the unaffected side than on the affected side in patients with unilateral moyamoya disease, but the difference decreases according to the contra... by Yuki Oichi (11840776)

“…<p>(A) shows the carotid canal area compared between the affected side and the unaffected side in patients with unilateral moyamoya disease, and the unaffected side is significantly wider than the affected side (p = 0.018). …”

Multivariable logistic regression analysis of the relationship of the date of a PHC visit with new visits, types of health events, procedure, and outcome of visits. by Taizo Sakata (21567847)

Subjects: